Exploring the scaffold universe of kinase inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 315-332

  Hu, Ye ^a   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYL GROUP; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE; TERTIARY AMINE; DRUG; ENZYME INHIBITOR; MOLECULAR LIBRARY; PHOSPHOTRANSFERASE;

ANALYTIC METHOD; ARTICLE; CYCLIC SKELETON; DRUG STRUCTURE; ENZYME ACTIVITY; GLOBAL STRUCUTURAL RELATIONSHIP; IC50; MATCHED MOLECULAR PAIR; RETROSYNTHETIC COMBINATORIAL ANALYSIS PROCEDURE; SCAFFOLD NETWORK; SCAFFOLD PROMISCUITY; SINGLE KINASE SCAFFOLD; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY;

DRUG DESIGN; ENZYME INHIBITORS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PHOSPHOTRANSFERASES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920983601     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501237k     Document Type: Article

References (24)

1. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S. Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists J. Med. Chem. 1988, 31, 2235-2246
2. Müller, G. Medicinal Chemistry of Target Family-Directed Masterkeys Drug Discovery Today 2003, 8, 681-691
3. Hu, Y.; Stumpfe, D. Bajorath. Lessons Learned from Molecular Scaffold Analysis J. Chem. Inf. Model. 2011, 51, 1743-1752
4. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry J. Chem. Inf. Comput. Sci. 1998, 38, 511-522
5. Bemis, G. W.; Murcko, M. A. The Properties of Known Drugs. 1. Molecular Frameworks J. Med. Chem. 1996, 39, 2887-2893
6. Xu, Y.-J.; Johnson, M. Algorithm for Naming Molecular Equivalence Classes Represented by Labeled Pseudographs J. Chem. Inf. Comput. Sci. 2001, 41, 181-185
7. Ward, R. A.; Goldberg, F. W., Eds. Kinase Drug Discovery; RSC: Cambridge, UK, 2011.
8. Levitzki, A. Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance Annu. Rev. Pharmacol. Toxicol. 2013, 53, 161-185
9. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lélias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors Nature Biotechnol. 2005, 23, 329-336
10. Metz, J. T.; Johnson, E. F.; Soni, N. B.; Merta, P. J.; Kifle, L.; Hajduk, P. J. Navigating the Kinome Nature Chem. Biol. 2011, 7, 200-202
11. Bento, A. P.; Gaulton, A.; Hersey, A.; Bellis, L. J.; Chambers, J.; Davies, M.; Krüger, F. A.; Light, Y.; Mak, L.; McGlinchey, S.; Nowotka, M.; Papadatos, G.; Santos, R.; Overington, J. P. The ChEMBL Bioactivity Database: An Update Nucleic Acids Res. 2014, 42, D1083-D1090
12. UniProt Consortium. Reorganizing the Protein Space at the Universal Protein Resource (UniProt). Nucleic Acids Res. 2012, 40, D142-D148.
13. Manning, G.; Whyte, D.; Martinez, R.; Hunter, T.; Sudarsanam, S. The Protein Kinase Complement of the Human Genome Science 2002, 298, 1912-1934
14. Kenny, P. W.; Sadowski, J. Structure Modification in Chemical Databases. In Chemoinformatics in Drug Discovery; Oprea, T. I., Ed.; Wiley-VCH: Weinheim, Germany, 2004; pp 271-285.
15. Hussain, J.; Rea, C. Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets J. Chem. Inf. Model. 2010, 50, 339-348
16. Hu, X.; Hu, Y.; Vogt, M.; Stumpfe, D.; Bajorath, J. MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs J. Chem. Inf. Model. 2012, 52, 1138-1145
17. OEChem, version 1.7.7; OpenEye Scientific Software, Inc.: Santa Fe, NM, 2012; http://www.eyesopen.com.
18. Hu, Y.; Bajorath, J. Many Drugs Contain Unique Scaffolds with Varying Structural Relationships to Scaffolds of Currently Available Bioactive Compounds Eur. J. Med. Chem. 2014, 76, 427-434
19. Hu, Y.; Bajorath, J. Compound Promiscuity-What Can We Learn From Current Data Drug Discovery Today 2013, 18, 644-650
20. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: a Software Environment for Integrated Models of Biomolecular Interaction Networks Genome Res. 2003, 13, 2498-2504
21. Hu, Y.; Furtmann, N.; Bajorath, J. Current Compound Coverage of the Kinome. J. Med. Chem., 2014, DOI 10.1021/jm5008159.
22. de la Vega de León, A.; Bajorath, J. Matched Molecular Pairs Derived by Retrosynthetic Fragmentation Med. Chem. Commun. 2014, 5, 64-67
23. Zhao, Z.; Wu, H.; Wang, L.; Liu, Y.; Knapp, S.; Liu, Q.; Gray, N. S. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS Chem. Biol. 2014, 9, 1230-1241
24. Hu, Y.; Bajorath, J. Kinase Inhibitors and Scaffolds. ZENODO, 2014; DOI: 10.5281/zenodo.11573.